Finch Therapeutics Group, Inc. (OTCPK: FNCH.Q)
Health Care · Biotechnology · US
$10.20
+0.99% today · -15.0% 1Y
Finch Therapeutics Group, Inc. (OTCPK: FNCH.Q) operates in the Biotechnology industry within the Health Care sector. The company is valued at $16.38M and employs 1 people.
Over the last twelve months the share price has lost 15.0%, trading between 2.00 and 16.10.
Tweenvest scores Finch Therapeutics Group, Inc. across four factors: quality 15/100. Its strongest factor is quality.
FNCH.Q price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $16.38M
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- -8.82
- Dividend yield
- —
- Beta (5Y)
- 1.01
- 52-week high
- $16.10
- 52-week low
- $2.00
- Avg volume (3M)
- —
- Shares outstanding
- 1.61M
- Employees
- 1
- Next earnings
- —
About Finch Therapeutics Group, Inc.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
- Founded
- 2014
- Listed since
- Mar 19, 2021
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.85 | +0.34% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.50 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.50 | +0.26% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $842.16 | +0.97% |
| argenx SEENXTBR: ARGX | $65.85B | €880.20 | -2.42% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $142.57 | -1.72% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.